Solventum (NYSE:SOLV) Updates FY 2026 Earnings Guidance
by Mitch Edgeman · The Markets DailySolventum (NYSE:SOLV – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.400-6.600 for the period, compared to the consensus earnings per share estimate of 6.350. The company issued revenue guidance of -.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on SOLV. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Mizuho set a $100.00 target price on Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Finally, BTIG Research raised shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Tuesday, December 2nd. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $91.36.
View Our Latest Stock Analysis on Solventum
Solventum Stock Up 2.9%
Solventum stock traded up $2.17 during mid-day trading on Thursday, hitting $77.25. The company’s stock had a trading volume of 1,914,488 shares, compared to its average volume of 1,054,143. Solventum has a 52-week low of $60.70 and a 52-week high of $88.20. The company has a market cap of $13.40 billion, a PE ratio of 8.90, a price-to-earnings-growth ratio of 6.74 and a beta of 0.35. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The firm’s 50 day moving average is $78.80 and its 200 day moving average is $76.18.
Solventum (NYSE:SOLV – Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, analysts anticipate that Solventum will post 6.58 earnings per share for the current year.
Solventum announced that its Board of Directors has initiated a share repurchase plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to buy up to 7.5% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. United Services Automobile Association purchased a new stake in shares of Solventum during the 1st quarter worth about $239,000. Woodline Partners LP increased its holdings in Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after buying an additional 3,377 shares during the last quarter. Intech Investment Management LLC raised its position in Solventum by 167.0% during the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after acquiring an additional 10,425 shares in the last quarter. First Trust Advisors LP lifted its stake in Solventum by 5.8% in the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after acquiring an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Solventum in the second quarter worth approximately $766,000.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.